Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis
<p><strong>Background:</strong><br /> Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), le...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cochrane Collaboration
2019
|